Drug Trial Radar · NCT07662798
A Study of Food Effect on Tersolisib (LY4064809) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 1, 2026
Primary completion
Sep 3, 2026
Study completion Sep 3, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to measure how food affects the amount of tersolisib that gets into the bloodstream. Each participant will receive two single oral doses of tersolisib, one under fasted conditions and one with either a high-fat or a low-fat meal. Blood tests will be performed to investigate how the body processes the study drug under each condition. For each participant, the study will last about 9 weeks and will include a stay in the Clinical Research Unit (CRU) lasting almost a month.
Conditions
- Healthy
Interventions
TersolisibDrug
Tersolisib administered orally
High-fat MealOther
High-fat Meal
Low-fat MealOther
Low-fat Meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of TersolisibTime frame: Predose on Day 1 Through Day 28
- PK: Area Under the Concentration Versus Time Curve (AUC) of TersolisibTime frame: Predose on Day 1 Through Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Lenexa Clinic
Lenexa, Kansas
ICON Early Phase Services, LLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.